Benzinga - by Benzinga Insights, Benzinga Staff Writer.
Revealing a significant insider sell on May 1, Peter J Wilkinson, SVP at Laboratory Corp (NYSE:LH), as per the latest SEC filing.
What Happened: Wilkinson's decision to sell 2,439 shares of Laboratory Corp was revealed in a Form 4 filing with the U.S. Securities and Exchange Commission on Wednesday. The total value of the sale is $498,358.
In the Thursday's morning session, Laboratory Corp's shares are currently trading at $199.78, experiencing a down of 0.76%.
Get to Know Laboratory Corp Better Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Financial Milestones: Laboratory Corp's Journey Positive Revenue Trend: Examining Laboratory Corp's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 4.57% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Interpreting Earnings Metrics:
- Gross Margin: With a low gross margin of 28.25%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
- Earnings per Share (EPS): The company excels with an EPS that surpasses the industry average. With a current EPS of 2.71, Laboratory Corp showcases strong earnings per share.
Valuation Overview:
- Price to Earnings (P/E) Ratio: The current P/E ratio of 43.02 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
- Price to Sales (P/S) Ratio: The current P/S ratio of 1.42 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
- EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation & Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 16.56, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.
Why Insider Transactions Are Important Considering insider transactions is valuable, but it's crucial to evaluate them in conjunction with other investment factors.
In the context of legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as outlined by Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are obligated to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
Pointing towards optimism, a company insider's new purchase signals their positive anticipation for the stock to rise.
Despite insider sells not always signaling a bearish sentiment, they can be driven by various factors.
A Closer Look at Important Transaction Codes For investors, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
Check Out The Full List Of Laboratory Corp's Insider Trades.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.